Статті в журналах з теми "EGFR / ErbB-1 / HER1"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "EGFR / ErbB-1 / HER1".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Elster, Naomi, Sinead Toomey, Yue Fan, Mattia Cremona, Clare Morgan, Karolina Weiner Gorzel, Una Bhreathnach, et al. "Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer." Therapeutic Advances in Medical Oncology 10 (January 1, 2018): 175883591877829. http://dx.doi.org/10.1177/1758835918778297.
Erben, Philipp, Felix Wezel, Ralph Wirtz, Thomas Martini, Doron Stein, Cleo-Aaron Weis, Arndt Hartmann, and Christian Bolenz. "Bedeutung der ERBB-Rezeptorfamilie beim Urothelkarzinom der Harnblase: mRNA-Expression und prognostische Relevanz." Aktuelle Urologie 48, no. 04 (July 27, 2017): 356–62. http://dx.doi.org/10.1055/s-0043-110403.
Hullmann, Grace, and Michael A. Azfer. "Immunogenic properties of outer membrane protein of Acinetobacter baumannii that loaded on chitosan nanoparticles." American Journal of BioMedicine 5, no. 1 (February 11, 2017): 32–44. http://dx.doi.org/10.18081/2333-5106/017-32-44.
Shen, Wang, Jeffrey Bacha, Dennis Brown, Sarath Kanekal, Neil Sankar, ZhenZhong Wang, Harry Pedersen, et al. "THER-01. PRECLINICAL DEVELOPMENT OF EO1001, A NOVEL IRREVERSIBLE BRAIN PENETRATING PAN-ErbB INHIBITOR." Neuro-Oncology Advances 1, Supplement_1 (August 2019): i10—i11. http://dx.doi.org/10.1093/noajnl/vdz014.044.
Ma, Fei, Qiao Li, Xiuwen Guan, Shanshan Chen, Zongbi Yi, Bo Lan, Puyuan Xing, et al. "Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 1035. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1035.
Choudhury, Noura, Alexa Campanile, Tatjana Antic, James Lloyd Wade, Walter Michael Stadler, Yusuke Nakamura, and Peter H. O'Donnell. "Afatinib activity in platinum-refractory metastatic urothelial carcinoma (UC) patients with ErbB alterations: Results of a phase II trial." Journal of Clinical Oncology 34, no. 2_suppl (January 10, 2016): 459. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.459.
Choudhury, Noura, Alexa Campanile, James Lloyd Wade, Tatjana Antic, Walter Michael Stadler, Yusuke Nakamura, and Peter H. O'Donnell. "Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial." Journal of Clinical Oncology 33, no. 7_suppl (March 1, 2015): 312. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.312.
Janjigian, Yelena Yuriy, David Ilson, David Paul Kelsen, Mark Schattner, Adriana Heguy, and Efsevia Vakiani. "A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS4144. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps4144.
Schuler, Martin H., David Planchard, James Chih-Hsin Yang, Joo-Hang Kim, Filippo De Marinis, Yuh-Min Chen, Caicun Zhou, et al. "Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 7557. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.7557.
Choudhury, Noura J., Alexa Campanile, Tatjana Antic, Kai Lee Yap, Carrie A. Fitzpatrick, James L. Wade, Theodore Karrison, Walter M. Stadler, Yusuke Nakamura, and Peter H. O’Donnell. "Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations." Journal of Clinical Oncology 34, no. 18 (June 20, 2016): 2165–71. http://dx.doi.org/10.1200/jco.2015.66.3047.
Chen, Bo, Ning Liao, Guo-Chun Zhang, Yulei Wang, Xiaoqing Chen, Liping Guo, Li Cao, et al. "Distinct mutational landscape between HR+ and HR- HER2+ early-stage breast cancer patients." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 543. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.543.
LI, Hongbing, Juan SÁNCHEZ-TORRES, Alan del CARPIO, Valentina SALAS, and Antonio VILLALOBO. "The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein." Biochemical Journal 381, no. 1 (June 22, 2004): 257–66. http://dx.doi.org/10.1042/bj20040515.
Yang, James Chih-Hsin, Martin H. Schuler, Nobuyuki Yamamoto, Kenneth John O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, et al. "LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations." Journal of Clinical Oncology 30, no. 18_suppl (June 20, 2012): LBA7500. http://dx.doi.org/10.1200/jco.2012.30.18_suppl.lba7500.
Harbeck, Nadia, Seock-Ah Im, Chiun-Sheng Huang, Young-Hyuck Im, Binghe Xu, Sara A. Hurvitz, Keun-Seok Lee, et al. "LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS649. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps649.
Kim, Joo-Hang, Francesco Grossi, Filippo De Marinis, Manuel Cobo, James Chih-Hsin Yang, Yury Ragulin, Igor N. Bondarenko, et al. "Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 7558. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.7558.
Jena, Bipulendu, Natalya Belousova, George T. McNamara, David Rushworth, Tiejuan Mi, Helen Huls, Richard E. Champlin, and Laurence JN Cooper. "Specifically Targeting the Interface Between HER1-HER3 Heterodimer on Breast Cancer to Limit Off-Target Effects Using Chimeric Antigen Receptor Designs with Improved T-Cell Energy Balance." Blood 124, no. 21 (December 6, 2014): 2151. http://dx.doi.org/10.1182/blood.v124.21.2151.2151.
Wu, Yi Long, Caicun Zhou, Cheng-Ping Hu, Ji Feng Feng, Shun Lu, Yunchao Huang, Wei Li, et al. "LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 8016. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8016.
Burtness, Barbara, Jean Bourhis, Jan Baptist Vermorken, Luyan Dai, Charlotte Lind, Eva Ehrnrooth, and Ezra E. W. Cohen. "LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS5599. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps5599.
Hamilton, Erika Paige, Manish R. Patel, Jordi Rodon, David S. Hong, Alison M. Schram, Pasi A. Janne, Patricia LoRusso, et al. "Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): TPS3665. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3665.
Geater, Sarayut Lucien, Caicun Zhou, Cheng-Ping Hu, Ji Feng Feng, Shun Lu, Yunchao Huang, Wei Li, et al. "LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 8061. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8061.
Jones, H. E., J. M. W. Gee, I. R. Hutcheson, and R. I. Nicholson. "Growth factor pathway switching: implications for the use of gefitinib and trastuzumab." Breast Cancer Online 9, no. 7 (June 26, 2006): 1–5. http://dx.doi.org/10.1017/s1470903106005451.
Paliga, Aleksandra, Horia Marginean, Bibianna Maria Purgina, Basile Tessier, Derek J. Jonker, and E. Celia Marginean. "The prognostic significance of ErbB-1 (EGFR), ErbB-2 (HER2), and c-MET overexpression in resectable gastric carcinoma (GC)." Journal of Clinical Oncology 32, no. 15_suppl (May 20, 2014): 3109. http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3109.
Gandhi, Leena, Jean-Charles Soria, Richard Bryce, and Benjamin Besse. "Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): TPS8124. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps8124.
Zimmermann, Michael T., Surendra Dasari, Rebecca L. Boddicker, Yu Zeng, Bruce Eckloff, Julie M. Cunningham, Yanhong Wu, et al. "Mutations Targeting the ErbB Pathway and MSC in Peripheral T-Cell Lymphoma." Blood 126, no. 23 (December 3, 2015): 2681. http://dx.doi.org/10.1182/blood.v126.23.2681.2681.
Collins, Denis M., Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, and John Crown. "Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer." Cancers 11, no. 6 (May 28, 2019): 737. http://dx.doi.org/10.3390/cancers11060737.
Yap, Timothy A., Laura Vidal, Jan Adam, Peter Stephens, James Spicer, Heather Shaw, Jooern Ang, et al. "Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors." Journal of Clinical Oncology 28, no. 25 (September 1, 2010): 3965–72. http://dx.doi.org/10.1200/jco.2009.26.7278.
Khalid, Zeena Ayad, Sazan Abdulwahab Mirza, and Azza Nazar Dhannoon. "Immunohistochemical Expression of EGFR and ErbB2/ HER2 in Human Meningioma. A Clinicopathological Study." NeuroQuantology 19, no. 8 (September 4, 2021): 20–26. http://dx.doi.org/10.14704/nq.2021.19.8.nq21108.
Smylie, M., G. R. Blumenschein, A. Dowlati, J. Garst, F. A. Shepherd, J. R. Rigas, H. Hassani, M. S. Berger, T. Zaks, and H. J. Ross. "A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 7611. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7611.
Merrick, D. T., J. Kittelson, R. Winterhalder, G. Kotantoulas, S. Ingeberg, R. L. Keith, T. C. Kennedy, Y. E. Miller, W. A. Franklin, and F. R. Hirsch. "Analysis of c-erb-1 (EGFR) and c-erb-2 (HER2) expression in bronchial dysplasia: Evaluation of potential targets for chemoprevention of lung cancer." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 7070. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7070.
Vanderwalde, Ari M., Matthew K. Stein, Lindsay Kaye Morris, Srishti Sareen, Saradasri Karri, Kruti Patel, Jennifer Sullivan, Lee Steven Schwartzberg, and Michael Gary Martin. "Distribution and pathogenicity of nsSNPs in receptor tyrosine kinases (RTKs) in non-small cell lung cancer (NSCLC) patients (pts)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e20618-e20618. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20618.
Hameed, M. R., L. Sharer, E. Cho, S. Aisner, L. Cao, Y. Tan, A. Mukherjee, A. Chenna, S. Singh, and C. Petropoulos. "The ERB family receptor dimerization in glioblastoma—An eTag assay analysis of 23 cases." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 1582. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.1582.
Laing, Lance G., Stefano Rossetti, Catherine Kuzmicki, Aaron Broege, Joanna Sabat, Salmaan Khan, Ian A. MacNeil, and Brian Sullivan. "Test identifies ovarian cancer patients with hyperactive c-Met and ErbB signaling tumors who may benefit from c-Met and pan-HER combination therapy." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e18038-e18038. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e18038.
De Greve, Jacques, Teresa Moran, Marie-Pascale Graas, Daniella Galdermans, Peter Vuylsteke, Jean-Luc Canon, Vikram K. Chand, Yali Fu, Dan Massey, and Johan Vansteenkiste. "Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 8063. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8063.
Ross, Jeffrey S., Siraj Mahamed Ali, Julia Andrea Elvin, Alexa Betzig Schrock, James Suh, Jo-Anne Vergilio, Shakti Ramkissoon, et al. "Targeted therapy for HER2 driven colorectal cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 3583. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3583.
Janjigian, Yelena Yuriy, Geoffrey Yuyat Ku, David H. Ilson, Michelle S. Boyar, Marinela Capanu, Joanne F. Chou, David Paul Kelsen, Tooba Imtiaz, Michael F. Berger, and Efsevia Vakiani. "A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer." Journal of Clinical Oncology 33, no. 3_suppl (January 20, 2015): 59. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.59.
Floros, Konstantinos V., Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernadó Morales, et al. "Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy." Proceedings of the National Academy of Sciences 115, no. 11 (February 23, 2018): E2594—E2603. http://dx.doi.org/10.1073/pnas.1717820115.
Peng, Xintong, Yanling Zhou, Yongguang Tao, and Shuang Liu. "Nasopharyngeal Carcinoma: The Role of the EGFR in Epstein–Barr Virus Infection." Pathogens 10, no. 9 (August 31, 2021): 1113. http://dx.doi.org/10.3390/pathogens10091113.
Massip-Copiz, María Macarena, Ángel G. Valdivieso, Mariángeles Clauzure, Consuelo Mori, Cristian J. A. Asensio, María Á. Aguilar, and Tomás A. Santa-Coloma. "Epidermal growth factor receptor activity upregulates lactate dehydrogenase A expression, lactate dehydrogenase activity, and lactate secretion in cultured IB3-1 cystic fibrosis lung epithelial cells." Biochemistry and Cell Biology 99, no. 4 (August 2021): 476–87. http://dx.doi.org/10.1139/bcb-2020-0522.
Luan, Haitao, Tameka A. Bailey, Robert J. Clubb, Bhopal C. Mohapatra, Aaqib M. Bhat, Sukanya Chakraborty, Namista Islam, et al. "CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis Degradation." Cancers 13, no. 16 (August 4, 2021): 3936. http://dx.doi.org/10.3390/cancers13163936.
Arora, P., B. D. Cuevas, A. Russo, G. L. Johnson, and J. Trejo. "Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion." Oncogene 27, no. 32 (March 31, 2008): 4434–45. http://dx.doi.org/10.1038/onc.2008.84.
Schram, Alison M., Jordi Rodon Ahnert, Manish R. Patel, Shekeab Jauhari, Jasgit C. Sachdev, Viola Weijia Zhu, Patricia LoRusso, et al. "Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 3086. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3086.
Collins, Denis, Norma O'Donovan, Naomi Walsh, Kathy Gately, Connla Edwards, Anthony Davies, Kenneth John O'Byrne, and John Crown. "The effects of lapatinib and neratinib on HER2 protein levels in breast cancer cell lines." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 637. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.637.
Agrawal, A., E. Gutteridge, J. M. W. Gee, R. I. Nicholson, and J. F. R. Robertson. "Overview of tyrosine kinase inhibitors in clinical breast cancer." Endocrine-Related Cancer 12, Supplement_1 (July 2005): S135—S144. http://dx.doi.org/10.1677/erc.1.01059.
Pohl, Michael, and Wolff Schmiegel. "Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow." Digestive Diseases 34, no. 5 (2016): 574–79. http://dx.doi.org/10.1159/000445267.
Sousa, Vítor, Joana Espírito Santo, Maria Silva, Teresa Cabral, Ana Maria Alarcão, Ana Gomes, Patrícia Couceiro, and Lina Carvalho. "EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study." Virchows Archiv 458, no. 5 (March 22, 2011): 571–81. http://dx.doi.org/10.1007/s00428-011-1062-5.
Wakelee, H. A., J. R. Molina, J. M. Fehling, J. L. Lensing, and B. I. Sikic. "A phase I study with exploratory pharmacodynamic endpoints of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients (pts) with advanced solid malignancies." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 14044. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14044.
Giaccone, Giuseppe, Ariel Lopez-Chavez, Anish Thomas, Arun Rajan, Mark Raffeld, Regan M. Duffy, Betsy Morrow, et al. "Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 7513. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7513.
Iqbal, S., B. Goldman, H. J. Lenz, C. M. Fenoglio-Preiser, and C. D. Blanke. "S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 4621. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4621.
Ang, J., C. Mikropoulos, F. Stavridi, S. Rudman, M. Uttenreuther-Fisher, M. Shahidi, K. Pemberton, S. Wind, J. de Bono, and J. F. Spicer. "A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e14541-e14541. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e14541.
O'Neill, Fiona, Stephen F. Madden, Martin Clynes, Padraig Doolan, John Crown, Sinead Aherne, and Robert O'Connor. "A gene expression profile indicative of early stage HER2 tyrosine kinase inhibitor response." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e11536-e11536. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e11536.